Expression of functional metallothionein isoforms in papillary thyroid cancer

Molecular and Cellular Endocrinology

Volumn 302, Issue 1, 2009, Pages 92-98

  Liu, Zhi Min ^a,b   Hasselt, C Andrew van ^a   Song, Fang Zhou ^b   Vlantis, Alexander C ^a   Cherian, M George ^c   Koropatnick, James ^c   Chen, George G ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Cadmium; Calcium; Cell cycle; ERK; Metallothionein; Papillary thyroid cancer

Indexed keywords

CADMIUM; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; METALLOTHIONEIN I; METALLOTHIONEIN II; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR;

ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PAPILLARY THYROID CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID CANCER;

BLOTTING, WESTERN; CARCINOMA, PAPILLARY; CELL CYCLE; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; METALLOTHIONEIN; PROTEIN ISOFORMS; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THYROID NEOPLASMS;

EID: 60549112324     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2008.12.017     Document Type: Article

References (39)

1. Ball D.W., Jin N., Rosen D.M., Dackiw A., Sidransky D., Xing M., and Nelkin B.D. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J. Clin. Endocrinol. Metab. 92 (2007) 4712-4718
2. Baris O., Mirebeau-Prunier D., Savagner F., Rodien P., Ballester B., Loriod B., Granjeaud S., Guyetant S., Franc B., Houlgatte R., Reynier P., and Malthiery Y. Gene profiling reveals specific oncogenic mechanisms and signaling pathways in oncocytic and papillary thyroid carcinoma. Oncogene 24 (2005) 4155-4161
3. Berridge M.J., Lipp P., and Bootman M.D. The versatility and universality of calcium signalling. Nat. Rev. Mol. Cell. Biol. 1 (2000) 11-21
4. Cai L., Wang G.J., Xu Z.L., Deng D.X., Chakrabarti S., and Cherian M.G. Metallothionein and apoptosis in primary human hepatocellular carcinoma (HCC) from northern China. Anticancer Res. 18 (1998) 4667-4672
5. Chakraborti T., Das S., Mondal M., Roychoudhury S., and Chakraborti S. Oxidant, mitochondria and calcium: an overview. Cell. Signal. 11 (1999) 77-85
6. Cherian M.G., Jayasurya A., and Bay B.H. Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat. Res. 533 (2003) 201-209
7. Chun J.H., Kim H.K., Kim E., Kim I.H., Kim J.H., Chang H.J., Choi I.J., Lim H.S., Kim I.J., Kang H.C., Park J.H., Bae J.M., and Park J.G. Increased expression of metallothionein is associated with irinotecan resistance in gastric cancer. Cancer Res. 64 (2004) 4703-4706
8. Datta J., Majumder S., Kutay H., Motiwala T., Frankel W., Costa R., Cha H.C., MacDougald O.A., Jacob S.T., and Ghoshal K. Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein alpha by phosphatidylinositol 3-kinase signaling cascade. Cancer Res. 67 (2007) 2736-2746
9. Deng D.X., Chakrabarti S., Waalkes M.P., and Cherian M.G. Metallothionein and apoptosis in primary human hepatocellular carcinoma and metastatic adenocarcinoma. Histopathology 32 (1998) 340-347
10. Duntas L.H. The role of selenium in thyroid autoimmunity and cancer. Thyroid 16 (2006) 455-460
11. Durak I., Bayram F., Kavutcu M., Canbolat O., and Ozturk H.S. Impaired enzymatic antioxidant defense mechanism in cancerous human thyroid tissues. J. Endocrinol. Invest. 19 (1996) 312-315
12. Ferrario C., Lavagni P., Gariboldi M., Miranda C., Losa M., Cleris L., Formelli F., Pilotti S., Pierotti M.A., and Greco A. Metallothionein 1G acts as an oncosupressor in papillary thyroid carcinoma. Lab. Invest. 88 (2008) 474-481
13. Figge J. Epidemiology of thyroid cancer. In: Wartofsky L. (Ed). Thyroid Cancer: A Comprehensive Guide To Clinical Management (1999), Humana Press, Totowa 77-83
14. Finn S.P., Smyth P., Cahill S., Streck C., O'Regan E.M., Flavin R., Sherlock J., Howells D., Henfrey R., Cullen M., Toner M., Timon C., O'Leary J.J., and Sheils O.M. Expression microarray analysis of papillary thyroid carcinoma and benign thyroid tissue: emphasis on the follicular variant and potential markers of malignancy. Virchows Arch. 450 (2007) 249-260
15. Galizia G., Ferraraccio F., Lieto E., Orditura M., Castellano P., Imperatore V., La Manna G., Pinto M., Ciardiello F., La Mura A., and De Vita F. p27 downregulation and metallothionein overexpression in gastric cancer patients are associated with a poor survival rate. J. Surg. Oncol. 93 (2006) 241-252
16. Hinkel A., Schmidtchen S., Palisaar R.J., Noldus J., and Pannek J. Identification of bladder cancer patients at risk for recurrence or progression: an immunohistochemical study based on the expression of metallothionein. J. Toxicol. Environ. Health A 71 (2008) 954-959
17. Huang Y., de la Chapelle A., and Pellegata N.S. Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma. Int. J. Cancer 104 (2003) 735-744
18. Joseph M.G., Banerjee D., Kocha W., Feld R., Stitt L.W., and Cherian M.G. Metallothionein expression in patients with small cell carcinoma of the lung: correlation with other molecular markers and clinical outcome. Cancer 92 (2001) 836-842
19. Kim M.H., Cho H.S., Jung M., Hong M.H., Lee S.K., Shin B.A., Ahn B.W., and Jung Y.D. Extracellular signal-regulated kinase and AP-1 pathways are involved in reactive oxygen species-induced urokinase plasminogen activator receptor expression in human gastric cancer cells. Int. J. Oncology 26 (2005) 1669-1674
20. Klaassen C.D., Liu J., and Choudhuri S. Metallothionein: an intracellular protein to protect against cadmium toxicity. Annu. Rev. Pharmacol. Toxicol. 39 (1999) 267-294
21. Lee S.S., Yang S.F., Ho Y.C., Tsai C.H., and Chang Y.C. The upregulation of metallothionein-1 expression in areca quid chewing-associated oral squamous cell carcinomas. Oral Oncol. 44 (2008) 180-186
22. Liu Z.M., Chen G.G., Shum C.K.Y., Vlantis A.C., Cherian M.G., and van Hasselt C.A. Induction of functional MT1 and MT2 isoforms by calcium in anaplastic thyroid cancer cells. FEBS Lett. 581 (2007) 2465-2472
23. Liu D., Liu Z., Condouris S., and Xing M. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. J. Clin. Endocrinol. Metab. 92 (2007) 2264-2271
24. Mano T., Shinohara R., Iwase K., Kotake M., Hamada M., Uchimuro K., Hayakawa N., Hayashi R., Nakai A., Ishizuki Y., and Nagasaka A. Changes in free radical scavengers and lipid peroxide in thyroid glands of various thyroid disorders. Horm. Metab. Res. 29 (1997) 351-354
25. Massague J. G1 cell-cycle control and cancer. Nature 432 (2004) 298-306
26. Mididoddi S., McGuirt J.P., Sens M.A., Todd J.H., and Sens D.A. Isoform -specific expression of metallothionein mRNA in the developing and adult human kidney. Toxicol. Lett. 85 (1996) 17-27
27. Nartey N., Cherian M.G., and Banerjee D. Immunohistochemical localization of metallothionein in human thyroid tumors. Am. J. Pathol. 129 (1987) 177-182
28. Nawaz M., Manzl C., Lacher V., and Krumschnabel G. Copper-induced stimulation of extracellular signal-regulated kinase in trout hepatocytes: the role of reactive oxygen species, Ca2+, and cell energetics and the impact of extracellular signal-regulated kinase signaling on apoptosis and necrosis. Toxicol. Sci. 92 (2006) 464-475
29. Nikiforova M.N., and Nikiforov Y.E. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert. Rev. Mol. Diagn. 8 (2008) 83-95
30. Sherr C.J. Cancer cell cycles. Science 274 (1996) 1672-1677
31. Shiraishi N., and Waalkes M.P. Enhancement of metallothionein gene expression in male Wistar (WF/NCr) rats by treatment with calmodulin inhibitors: potential role of calcium regulatory pathways in metallothionein induction. Toxicol. Appl. Pharmacol. 125 (1994) 97-103
32. Stennard F.A., Holloway A.F., Hamilton J., and West A.K. Characterization of six additional human metallothionein genes. Biochim. Biophy. Acta 1218 (1994) 357-365
33. Surowiak P., Materna V., Maciejczyk A., Pudełko M., Markwitz E., Spaczyński M., Dietel M., Zabel M., and Lage H. Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome. Virchows Archiv. 450 (2007) 279-285
34. Theocharis S.E., Margeli A.P., and Koutselinis A. Metallothionein: a multifunctional protein from toxicity to cancer. Int. J. Biol. Markers 18 (2003) 162-169
35. Wei H., Desouki M.M., Lin S., Xiao D., Franklin R.B., and Feng P. Differential expression of metallothioneins (MTs) 1, 2, and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues. Mol. Cancer 7 (2008) 7
36. Weinlich G., and Zelger B. Metallothionein overexpression, a highly significant prognostic factor in thin melanoma. Histopathology 51 (2007) 280-283
37. Wu W.S., Tsai R.K., Chang C.H., Wang S., Wu J.R., and Chang Y.X. Reactive oxygen species mediated sustained activation of protein kinase C alpha and extracellular signal-regulated kinase for migration of human hepatoma cell Hepg2. Mol. Cancer Res.: MCR 4 (2006) 747-758
38. Yamasaki M., Nomura T., Sato F., and Mimata H. Metallothionein is up-regulated under hypoxia and promotes the survival of human prostate cancer cells. Oncol. Rep. 18 (2007) 1145-1153
39. Yoshida M., Saegusa Y., Fukuda A., Akama Y., and Owada S. Measurement of radical-scavenging ability in hepatic metallothionein of rat using in vivo electron spin resonance spectroscopy. Toxicology 213 (2005) 74-80